Loading
Connect hospital records across countries so that questions about how treatments work in real patients can be answered in weeks without moving the data, to a standard regulators accept.
Real-world evidence is fragmented, of variable quality and rarely accepted for decisions beyond safety. Federated analytics (OHDSI, DARWIN EU, Flatiron-style curated networks) demonstrate feasibility. The proposal is a global federated oncology network: common data model with oncology extensions, automated quality scoring, pre-registered analysis protocols executed locally with only aggregates shared, external control arm generation for rare indications, and a regulatory framework specifying when network evidence can support label expansions, pricing revisions and post-approval commitments.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Tempus AI, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Foundation Medicine (Roche), Tempus AI, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Real-world evidence, Weak real-world evidence and registries, Data silos.